Targeting the Glutamatergic System to Treat Major Depressive Disorder: Rationale and Progress to Date

Major depressive disorder (MDD) is a severe, debilitating medical illness that affects millions of individuals worldwide. The young age of onset and chronicity of the disorder has a significant impact on the long-term disability that affected individuals face. Most existing treatments have focused o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs (New York, N.Y.) N.Y.), 2012-07, Vol.72 (10), p.1313-1333
Hauptverfasser:	Mathews, Daniel C., Henter, Ioline D., Zarate, Carlos A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult and adolescent clinical studies Antidepressive Agents - administration & dosage Antidepressive Agents - therapeutic use Biological and medical sciences Depression Depressive Disorder, Major - drug therapy Depressive Disorder, Major - immunology Depressive Disorder, Major - metabolism Glutamic Acid - metabolism Humans Internal Medicine Ketamine - administration & dosage Ketamine - therapeutic use Leading Article Medical sciences Medicine Medicine & Public Health Molecular Targeted Therapy Mood disorders Neuropharmacology Pharmacology. Drug treatments Pharmacology/Toxicology Pharmacotherapy Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Randomized Controlled Trials as Topic Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!